Natera, Inc. ($NTRA) Stock Forecast: Down 7.8% Today

What is Natera, Inc.?

Natera (NTRA) is a diagnostics company specializing in women's health, oncology, and organ health. Today, the stock experienced a strong bearish movement in the market.

Why is Natera, Inc. going down?

NTRA stock is down 7.8% on Apr 10, 2026 19:25

• The court ruling awarding Natera a 30% royalty on post-injunction revenues from MRD patents against ArcherDx and Invitae was initially seen as a positive development, leading to a slight increase in premarket trading. However, the market may have reacted negatively due to concerns about high cash burn and challenges in clinical trials and reimbursement.
• The addition of director Eric H. Rubin to Natera's insider roster, while providing transparency, did not have a significant impact on the stock movement.
• Despite the favorable court decisions strengthening Natera's intellectual property portfolio, the market may have been influenced by the potential financial implications of the royalty payments on the company's overall performance.
• Analysts revising earnings upwards and the positive influence on stock valuation could indicate long-term growth potential, but the current overvaluation concerns raised in the analysis may have contributed to the bearish market movement.

NTRA Price Chart

NTRA Technical Analysis

NTRA News

Court Win on MRD Patents and Royalties Might Change The Case For Investing In Natera (NTRA)

Natera recently secured a favorable court ruling, upholding the validity of its three MRD patents and granting a 30% royalty on infringing product sales. This decision bolsters Natera's intellectual property in molecular residual disease testing, potentially enhancing its market position and revenue outlook. While strengthening Natera's investment narrative, the article notes that investors should still consider risks such as high cash burn and challenges in clinical trials and reimbursement.

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntra/natera/news/court-win-on-mrd-patents-and-royalties-might-change-the-case

Director Eric H. Rubin joins Natera (NTRA) insider roster with Form 3 filing

Natera, Inc. (NTRA) director Eric H. Rubin has filed an initial Form 3 with the SEC, formally establishing his status as an insider. This filing indicates that Rubin is a director of the company and brings him under insider reporting requirements, though it does not report any beneficial ownership of securities or trading activity. The Form 3 serves as an initial statement of beneficial ownership, providing transparency on his new insider role.

https://www.stocktitan.net/sec-filings/NTRA/form-3-natera-inc-initial-statement-of-beneficial-ownership-d9ef1efdbc22.html

Judge Hands Natera 30% Ongoing Royalty In MRD Patent Battle

A Delaware court has awarded Natera a 30% ongoing royalty on post-injunction revenues related to its MRD patents, building on a previous 20.5% royalty for pre-injunction sales. The court also upheld the validity and infringement findings of Natera's patents against ArcherDx and Invitae, strengthening Natera's intellectual property portfolio. Natera's shares saw a slight increase in premarket trading following the announcement, and the company is expected to release its next financial update in May 2026.

https://www.benzinga.com/markets/equities/26/04/51727487/judge-hands-natera-30-ongoing-royalty-in-mrd-patent-battle

Natera Says Court Orders 30% Royalties From ArcherDx, Invitae on Post-Injunction Sales

A court has ordered ArcherDx and Invitae to pay a 30% royalty to Natera for post-injunction sales. This decision follows a patent dispute and is expected to impact the financial performance of the involved diagnostic companies. Natera, a diagnostics company focusing on women's health, oncology, and organ health, will receive these royalties.

https://www.marketscreener.com/news/natera-says-court-orders-30-royalties-from-archerdx-invitae-on-post-injunction-sales-ce7e50dbd189f726

Natera wins 30% ongoing royalty in patent case against Invitae By Investing.com

Natera Inc. has won a court decision granting it a 30% ongoing royalty on post-injunction revenues from certain minimal residual disease-related product sales by ArcherDx and Invitae. This ruling follows an earlier injunction and upholds the validity of Natera's MRD patents. The company, trading at $210.83 with a market capitalization of $29.88 billion, has seen its stock valuation positively influenced, with analysts revising earnings upwards despite an InvestingPro analysis suggesting it is currently overvalued.

https://in.investing.com/news/company-news/natera-wins-30-ongoing-royalty-in-patent-case-against-invitae-93CH-5329628

Trending Today

Heating Oil ($HEATOIL) Commodity Forecast: Down 5.1% Today

Amylyx Pharmaceuticals ($AMLX) Stock Forecast: Down 5.1% Today

Check Point Software Technologies Ltd. ($CHKP) Stock Forecast: Down 5.2% Today

Palo Alto Networks Inc. ($PANW) Stock Forecast: Down 5.9% Today

TripAdvisor Inc. ($TRIP) Stock Forecast: Down 5.3% Today

Novavax Inc. ($NVAX) Stock Forecast: Down 5.2% Today

Natera, Inc. ($NTRA) Stock Forecast: Down 7.8% Today

ServiceNow Inc. ($NOW) Stock Forecast: Down 7.4% Today

Jetblue Airways Corporation ($JBLU) Stock Forecast: Down 5.1% Today

Akamai Technologies Inc. ($AKAM) Stock Forecast: Down 17.4% Today

Natera, Inc. Price History

31.02.2026 - NTRA Stock was up 5.1%

• Increased positions by Dakota Wealth Management and DAVENPORT & Co LLC suggest growing institutional interest, which has contributed to the bullish movement.
• Although there is strong institutional ownership, insider selling by CEO Steven Leonard Chapman and others may have caused initial uncertainty among investors.
• Natera's positive Q4 earnings report, surpassing expectations, likely boosted investor confidence and supported the bullish movement.
• Despite being considered undervalued by some estimates, recent share price weakness may have prompted profit-taking and a temporary decrease in the stock price.

31.02.2026 - NTRA Stock was up 6.5%

• Zevenbergen Capital Investments LLC decreased its stake in Natera, Inc. by 18%, while other institutional investors like Dakota Wealth Management and DAVENPORT & Co LLC have shown increased interest, reflecting diverse sentiments within the market.
• The positive development concerning Natera's Signatera™ MRD test aiding older women with breast cancer to avoid surgery likely contributed to the bullish movement, highlighting the company's advanced and impactful technology.
• Despite recent insider selling, including by the CEO, robust quarterly results surpassing expectations have upheld analyst confidence in Natera, with a "Moderate Buy" consensus and an average price target of $253.47, potentially fueling investor confidence and propelling the stock price higher.
• The decline in Natera's shares on March 30 may have been a temporary setback amidst generally positive sentiment, with Wall Street analysts forecasting a substantial upside and maintaining an "Outperform" recommendation, signaling a possible buying opportunity for investors.

01.03.2026 - NTRA Stock was up 5.1%

• The bullish movement in Natera Inc. (NTRA) today could be attributed to the positive results from the Signatera molecular residual disease (MRD) test, particularly in identifying breast cancer patients who may avoid surgery, boosting investor confidence in the company's innovative technology.
• Despite the recent share sell-off by Zevenbergen Capital Investments LLC, the overall market sentiment remains positive, with increased interest from other institutional investors and strong quarterly results beating expectations, supporting the stock's upward momentum.
• The study showcasing the efficacy of Signatera in guiding treatment decisions for older women with early-stage breast cancer likely contributed to the stock's bullish movement, as it highlights the potential market expansion and adoption of Natera's testing solutions.

04.02.2026 - NTRA Stock was up 5.8%

• The Chief Legal Officer of Natera receiving a significant number of restricted stock units (RSUs) aligns his incentives with the company's performance, indicating confidence in the company's future prospects.
• Mentioned company's reiteration of a Buy rating and positive revenue forecast for 2026 boosted investor confidence, leading to an increase in Natera's stock price.
• Despite a price target cut for Natera by a specific investment firm, other analysts maintaining Buy ratings and positive outlooks on the company's earnings and revenue growth contributed to the bullish market movement.
• The overall positive sentiment towards Natera, driven by strong Q4 results and optimistic forecasts, outweighed concerns over recent market volatility and inflation, leading to the stock's upward trajectory.

09.03.2026 - NTRA Stock was down 5.5%

• The bearish movement in Natera's stock today could be attributed to the Executive Chairman exercising stock options and using shares for taxes. This could have potentially raised concerns among investors about insider activities and the company's financial health.
• Despite Citi maintaining a Buy rating and a target price of $300 for Natera, the market might have reacted negatively to the news of insider selling and the challenges the company faces in profitability.
• The positive sentiment around Natera's upside potential and strong growth of Signatera, as mentioned by billionaire investor Stan Druckenmiller and financial analysts, could be overshadowed by short-term concerns leading to the bearish movement in the stock today.
• Investors will likely keep a close eye on Natera's upcoming earnings and financial performance to gauge its future trajectory, balancing the positive long-term outlook with the immediate challenges the company faces.

18.01.2026 - NTRA Stock was up 5.5%

• Anticipation and positive sentiment among investors were fueled by Natera's announcement of the upcoming release of its fourth quarter and full-year results.
• Institutional investors, such as Zweig DiMenna Associates LLC, increased their stake, indicating confidence in Natera's future performance and contributing to the bullish trend.
• Despite some company insiders selling off shares, the market remains optimistic about Natera's growth potential, evident from the stock's positive movement.
• An average price target of $249.20 alongside analysts' "Moderate Buy" consensus rating bode well for Natera, reinforcing the bullish market sentiment.

12.02.2026 - NTRA Stock was down 5.3%

• The downward movement in NTRA stock recently could be linked to a series of insider selling actions by senior executives, such as the President, CFO, and CEO, causing apprehension among investors regarding the company's future trajectory.
• Despite the positive performance in Q4 earnings, the pessimistic yearly EPS forecast and insider selling transactions might have outweighed the favorable revenue numbers, resulting in reduced investor trust and a subsequent dip in the stock value.
• The recurrent trend of insider sales, even after outperforming analyst estimates, may imply a disconnect between key individuals within the company and market sentiments, fostering uncertainty and contributing to the current bearish sentiment in NTRA stock.

27.02.2026 - NTRA Stock was down 5.1%

• Despite the launch of the Zenith Genomic Assay, Natera (NTRA) witnessed a bearish movement in the market.
• The stock's decline could be related to perceptions of the company being overvalued based on a Price-to-Sales ratio comparison, despite being considered undervalued in a Discounted Cash Flow analysis.
• Insider selling by the CFO and CEO, along with the company's lack of profitability and negative net margin, may have increased investor apprehensions and influenced the market's bearish trend.
• Investors are possibly reevaluating their positions in Natera (NTRA) after the recent downturn, despite the company's solid historical performance and favorable outlook from financial analysts.

10.03.2026 - NTRA Stock was down 5.6%

• The bearish movement in Natera's stock today could be attributed to profit-taking by investors after a recent uptrend following positive legal outcomes.
• The appointment of Director Eric H. Rubin to the insider roster may have raised concerns among investors about potential future decisions or changes within the company.
• Despite the positive rulings in the patent disputes and the increase in royalties, the market may have reacted negatively due to uncertainties surrounding the financial impact on Natera and its competitors.
• The insider activity of the Executive Chairman, Matthew Rabinowitz, exercising stock options and selling shares to cover tax obligations could have also contributed to the downward pressure on the stock price as investors may interpret this as a lack of confidence in the company's future prospects.

10.03.2026 - NTRA Stock was down 7.8%

• The court ruling awarding Natera a 30% royalty on post-injunction revenues from MRD patents against ArcherDx and Invitae was initially seen as a positive development, leading to a slight increase in premarket trading. However, the market may have reacted negatively due to concerns about high cash burn and challenges in clinical trials and reimbursement.
• The addition of director Eric H. Rubin to Natera's insider roster, while providing transparency, did not have a significant impact on the stock movement.
• Despite the favorable court decisions strengthening Natera's intellectual property portfolio, the market may have been influenced by the potential financial implications of the royalty payments on the company's overall performance.
• Analysts revising earnings upwards and the positive influence on stock valuation could indicate long-term growth potential, but the current overvaluation concerns raised in the analysis may have contributed to the bearish market movement.

27.01.2026 - NTRA Stock was down 6.6%

• Notable insider selling of Natera shares could be influencing the bearish trend, possibly indicating reservations or a lack of confidence among company insiders.
• Despite promising results from Phase 2 trials related to head and neck cancer, the market response may have been negative due to concerns surrounding the upcoming earnings announcement, with analysts predicting a per-share loss.
• The expectation of an unfavorable EPS in the forthcoming earnings report may have outshone the positive trial outcomes, contributing to a pessimistic outlook among investors.
• The divergence between the favorable trial results and the projected earnings loss could be causing uncertainty and fluctuations in Natera's stock value, resulting in the observed bearish sentiment in the market.

11.02.2026 - NTRA Stock was down 5.1%

• Quantbot Technologies LP and Victory Capital Management Inc. both made significant moves in their stakes with Natera, indicating conflicting sentiments among institutional investors.
• The increased insider selling by CEO and CFO, despite strong earnings and revenue beats, may have raised concerns among investors about the company's future performance.
• The mixed valuation assessments, with one model suggesting undervaluation and another pointing to an expensive sales multiple, could have contributed to the bearish market movement as investors reevaluate Natera's true worth.
• Overall, the combination of insider selling, conflicting institutional investor actions, and valuation uncertainties likely led to the bearish movement in Natera's stock today.